Pheochromocytoma-Pipeline Review, H2 2015

Pheochromocytoma-Pipeline Review, H2 2015

  • Products Id :- GMDHC7396IDB
  • |
  • Pages: 71
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pheochromocytoma-Pipeline Review, H2 2015


Global Markets Direct's, 'Pheochromocytoma-Pipeline Review, H2 2015', provides an overview of the Pheochromocytoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pheochromocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pheochromocytoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Pheochromocytoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pheochromocytoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pheochromocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pheochromocytoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pheochromocytoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pheochromocytoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Pheochromocytoma Overview 6

Therapeutics Development 7

Pipeline Products for Pheochromocytoma-Overview 7

Pipeline Products for Pheochromocytoma-Comparative Analysis 8

Pheochromocytoma-Therapeutics under Development by Companies 9

Pheochromocytoma-Therapeutics under Investigation by Universities/Institutes 10

Pheochromocytoma-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Pheochromocytoma-Products under Development by Companies 13

Pheochromocytoma-Products under Investigation by Universities/Institutes 14

Pheochromocytoma-Companies Involved in Therapeutics Development 15

Exelixis, Inc. 15

Genzyme Corporation 16

MediaPharma s.r.l. 17

Pfizer Inc. 18

Progenics Pharmaceuticals, Inc. 19

Valeant Pharmaceuticals International, Inc. 20

Pheochromocytoma-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 29

cabozantinib s-malate-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

iobenguane sulfate I 131-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

metyrosine-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

MPHE-001B-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

S-43126-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

sunitinib malate-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

vandetanib-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Pheochromocytoma-Recent Pipeline Updates 48

Pheochromocytoma-Product Development Milestones 65

Featured News & Press Releases 65

Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015 65

Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma 65

Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015 66

Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma 66

Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma 67

Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications 68

Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

Number of Products under Development for Pheochromocytoma, H2 2015 7

Number of Products under Development for Pheochromocytoma-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Number of Products under Investigation by Universities/Institutes, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 11

Comparative Analysis by Early Stage Development, H2 2015 12

Products under Development by Companies, H2 2015 13

Products under Investigation by Universities/Institutes, H2 2015 14

Pheochromocytoma-Pipeline by Exelixis, Inc., H2 2015 15

Pheochromocytoma-Pipeline by Genzyme Corporation, H2 2015 16

Pheochromocytoma-Pipeline by MediaPharma s.r.l., H2 2015 17

Pheochromocytoma-Pipeline by Pfizer Inc., H2 2015 18

Pheochromocytoma-Pipeline by Progenics Pharmaceuticals, Inc., H2 2015 19

Pheochromocytoma-Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015 20

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Stage and Target, H2 2015 23

Number of Products by Stage and Mechanism of Action, H2 2015 25

Number of Products by Stage and Route of Administration, H2 2015 27

Number of Products by Stage and Molecule Type, H2 2015 28

Pheochromocytoma Therapeutics-Recent Pipeline Updates, H2 2015 48

List of Figures

Number of Products under Development for Pheochromocytoma, H2 2015 7

Number of Products under Development for Pheochromocytoma-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 11

Comparative Analysis by Early Stage Products, H2 2015 12

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Top 10 Targets, H2 2015 22

Number of Products by Stage and Top 10 Targets, H2 2015 22

Number of Products by Top 10 Mechanism of Actions, H2 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 24

Number of Products by Top 10 Routes of Administration, H2 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26

Number of Products by Stage and Top 10 Molecule Types, H2 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Exelixis, Inc.

Genzyme Corporation

MediaPharma s.r.l.

Pfizer Inc.

Progenics Pharmaceuticals, Inc.

Valeant Pharmaceuticals International, Inc.

Pheochromocytoma Therapeutic Products under Development, Key Players in Pheochromocytoma Therapeutics, Pheochromocytoma Pipeline Overview, Pheochromocytoma Pipeline, Pheochromocytoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 143760
Site License
USD 4000 INR 287520
Corporate User License
USD 6000 INR 431280



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]